0001823239-26-000024
SEC filingQ1 delivered strong revenue growth and gross margin expansion from CleanCap COVID vaccine orders and 2025 Corporate Realignment efficiencies, narrowing losses and generating positive cash flow despite operating expenses.
Gross profit rose sharply to $33.7 million from $7.7 million, expanding the gross margin to 51.2%. The increase in gross profit margin as a percentage of sales was primarily attributable to product mix and decreased expenses driven by the 2025 Corporate Realignment Plan. Cost of revenue also includes adjustments for excess, obsolete or expired inventory, and idle capacity, which were better managed this quarter. These factors transformed profitability at the gross level, enabling better absorption of operating costs.
Operating income improved to a loss of $2.2 million from $49.2 million, a 95.6% reduction. Net income narrowed to a loss of $3.7 million from $29.9 million, with diluted EPS at -$0.02 versus -$0.21. The 2025 Corporate Realignment Plan contributed to expense efficiencies, though specific operating expense details remain within standard R&D and SG&A compositions including salaries, benefits, stock-based compensation, and facilities costs. Management expects selling, general and administrative expenses to decrease year-over-year in future periods from Realignment implementation, while R&D costs remain relatively consistent due to ongoing initiatives.
Cash flow from operating activities flipped to $8.7 million positive from -$9.4 million, after $4.4 million in capital expenditures, generating $4.2 million in free cash flow. The company has financed operations primarily from cash flow from operations, borrowings under long-term debt agreements, and sales of Class A common stock. This positive cash generation supports liquidity amid the Realignment and positions the business for sustained recovery as COVID-related orders stabilize and cost structure optimizes.